Compare TTRX & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTRX | JELD |
|---|---|---|
| Founded | 2015 | 1960 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 152.5M |
| IPO Year | N/A | 2016 |
| Metric | TTRX | JELD |
|---|---|---|
| Price | $8.07 | $1.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | ★ $8.00 | $3.43 |
| AVG Volume (30 Days) | 128.5K | ★ 1.3M |
| Earning Date | 05-31-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,211,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $0.93 |
| 52 Week High | $11.69 | $6.98 |
| Indicator | TTRX | JELD |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 36.39 |
| Support Level | $4.40 | $0.93 |
| Resistance Level | $11.69 | $2.06 |
| Average True Range (ATR) | 1.04 | 0.09 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 4.52 | 20.87 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.